TY - JOUR
T1 - Early molecular biomarkers predicting the evolution of allergic rhinitis and its comorbidities
T2 - A longitudinal multicenter study of a patient cohort
AU - for the Italian Pediatric Allergy Network (I-PAN)
AU - Cipriani, Francesca
AU - Tripodi, Salvatore
AU - Panetta, Valentina
AU - Perna, Serena
AU - Potapova, Ekaterina
AU - Dondi, Arianna
AU - Bernardini, Roberto
AU - Caffarelli, Carlo
AU - Casani, Antonella
AU - Cervone, Rosa
AU - Chini, Loredana
AU - Comberiati, Pasquale
AU - De Castro, Giovanna
AU - Miraglia Del Giudice, Michele
AU - Dello Iacono, Iride
AU - Di Rienzo Businco, Andrea
AU - Gallucci, Marcella
AU - Giannetti, Arianna
AU - Mastrorilli, Carla
AU - Moschese, Viviana
AU - Pelosi, Simone
AU - Sfika, Ifigenia
AU - Varin, Elena
AU - Villella, Valeria
AU - Zicari, Anna Maria
AU - Brindisi, Giulia
AU - Ricci, Giampaolo
AU - Matricardi, Paolo Maria
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Background: Pollen-related seasonal allergic rhinoconjunctivitis (SAR) is a very frequent pediatric disease in Westernized countries. Risk factors and disease phenotypes have been thoroughly examined in several cross-sectional studies. By contrast, only a few studies have examined disease evolution in patient cohorts. We investigated predictive biomarkers of disease evolution in a large cohort of children with SAR. Methods: During 2015-2017 (follow-up), we re-examined 401 patients from those enrolled in 2009-2011 (baseline) by the “Panallergens in Pediatrics” study, a large multicenter survey of Italian children with SAR. Information on clinical history (standard questionnaire, AllergyCARD®; TPS, Italy) and skin prick tests for inhalant and foods extracts (ALK-Abelló, Hørsholm, Denmark) was acquired as at baseline visit. Evolution in clinical and sensitization data of patients was analyzed over time, as well as their association with the main baseline characteristics and atopy risk factors. Results: The average age of participants was 10.4 ± 3.4 years at baseline and 16.2 ± 3.6 years at follow-up. SAR persisted in 93.3% of patients at follow-up and became more frequently associated with asthma (from 36.7% at baseline to 48.6% at follow-up) and oral allergy syndrome (OAS, from 23.4% to 37.7%). Compared to baseline, the prevalence of skin sensitization to some pollens (Phleum pratense, Corylus avellana, Platanus acerifolia, Artemisia vulgaris) and vegetables (hazelnut, wheat, and apple) significantly decreased at follow-up. Earlier onset of SAR and polysensitization at baseline were associated with incident asthma at follow-up. The presence at baseline of serum IgE to the following allergen molecules was identified as biomarkers of clinical evolution: (a) Phl p 1, for persistence of SAR; (b) Phl p 5, for persistence of both rhinitis and asthma; (c) Pru p 3, for new onset of asthma; (d) Bet v 1, for persistence of OAS. Conclusions: Seasonal allergic rhinoconjunctivitis is clinically heterogeneous in its evolution from childhood to adolescence. The detection of serum IgE to specific molecules (Phl p 1, Phl p 5, Bet v 1, Pru p 3) may be useful as biomarkers to predict SAR persistence and future onset of comorbidities, such as asthma and/or OAS.
AB - Background: Pollen-related seasonal allergic rhinoconjunctivitis (SAR) is a very frequent pediatric disease in Westernized countries. Risk factors and disease phenotypes have been thoroughly examined in several cross-sectional studies. By contrast, only a few studies have examined disease evolution in patient cohorts. We investigated predictive biomarkers of disease evolution in a large cohort of children with SAR. Methods: During 2015-2017 (follow-up), we re-examined 401 patients from those enrolled in 2009-2011 (baseline) by the “Panallergens in Pediatrics” study, a large multicenter survey of Italian children with SAR. Information on clinical history (standard questionnaire, AllergyCARD®; TPS, Italy) and skin prick tests for inhalant and foods extracts (ALK-Abelló, Hørsholm, Denmark) was acquired as at baseline visit. Evolution in clinical and sensitization data of patients was analyzed over time, as well as their association with the main baseline characteristics and atopy risk factors. Results: The average age of participants was 10.4 ± 3.4 years at baseline and 16.2 ± 3.6 years at follow-up. SAR persisted in 93.3% of patients at follow-up and became more frequently associated with asthma (from 36.7% at baseline to 48.6% at follow-up) and oral allergy syndrome (OAS, from 23.4% to 37.7%). Compared to baseline, the prevalence of skin sensitization to some pollens (Phleum pratense, Corylus avellana, Platanus acerifolia, Artemisia vulgaris) and vegetables (hazelnut, wheat, and apple) significantly decreased at follow-up. Earlier onset of SAR and polysensitization at baseline were associated with incident asthma at follow-up. The presence at baseline of serum IgE to the following allergen molecules was identified as biomarkers of clinical evolution: (a) Phl p 1, for persistence of SAR; (b) Phl p 5, for persistence of both rhinitis and asthma; (c) Pru p 3, for new onset of asthma; (d) Bet v 1, for persistence of OAS. Conclusions: Seasonal allergic rhinoconjunctivitis is clinically heterogeneous in its evolution from childhood to adolescence. The detection of serum IgE to specific molecules (Phl p 1, Phl p 5, Bet v 1, Pru p 3) may be useful as biomarkers to predict SAR persistence and future onset of comorbidities, such as asthma and/or OAS.
KW - allergic rhinitis
KW - asthma
KW - Bet v 1
KW - biomarkers
KW - children
KW - comorbidities
KW - IgE
KW - longitudinal study
KW - Phl p 1
KW - Phl p 5
KW - pollen
KW - prediction
KW - Pru p 3
UR - http://www.scopus.com/inward/record.url?scp=85063909558&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063909558&partnerID=8YFLogxK
U2 - 10.1111/pai.13036
DO - 10.1111/pai.13036
M3 - Article
AN - SCOPUS:85063909558
SN - 0905-6157
VL - 30
SP - 325
EP - 334
JO - Pediatric Allergy and Immunology
JF - Pediatric Allergy and Immunology
IS - 3
ER -